1,747 Shares of AbbVie Inc. $ABBV Bought by Presper Financial Architects LLC

Presper Financial Architects LLC acquired a new stake in AbbVie Inc. (NYSE:ABBV – Free Report) in the 3rd quarter, according to its most recent filing with the SEC. The fund acquired 1,747 shares of the company’s stock, valued at approximately $457,000. AbbVie accounts for about 0.3% of Presper Financial Architects LLC’s investment portfolio, making the stock its 29th biggest holding.

Several other institutional investors and hedge funds have also modified their holdings of the business. Western Wealth Management LLC increased its position in shares of AbbVie by 2.4% during the third quarter. Western Wealth Management LLC now owns 38,339 shares of the company’s stock worth $10,029,000 after acquiring an additional 899 shares in the last quarter. Francis Financial Inc. raised its holdings in shares of AbbVie by 13.9% during the third quarter. Francis Financial Inc. now owns 1,274 shares of the company’s stock worth $333,000 after acquiring an additional 155 shares during the period. Intech Investment Management LLC lifted its position in AbbVie by 9.8% in the 3rd quarter. Intech Investment Management LLC now owns 50,653 shares of the company’s stock valued at $13,250,000 after acquiring an additional 4,505 shares in the last quarter. Bridgewealth Advisory Group LLC lifted its position in AbbVie by 6.1% in the 3rd quarter. Bridgewealth Advisory Group LLC now owns 1,248 shares of the company’s stock valued at $326,000 after acquiring an additional 72 shares in the last quarter. Finally, Morse Asset Management Inc lifted its position in AbbVie by 3.1% in the 3rd quarter. Morse Asset Management Inc now owns 19,012 shares of the company’s stock valued at $4,973,000 after acquiring an additional 571 shares in the last quarter. 70.23% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts recently weighed in on ABBV shares. JPMorgan Chase & Co. upped their target price on shares of AbbVie from $285.00 to $300.00 and gave the stock an “overweight” rating in a research note on Thursday, October 8th. Wolfe Research raised AbbVie from a “peer perform” rating to an “outperform” rating and lifted their price target for the company from $235.00 to $300.00 in a research note on Thursday, August 13th. Piper Sandler boosted their price target on AbbVie from $298.00 to $303.00 and gave the company an “overweight” rating in a report on Thursday, August 20th. Weiss Ratings raised AbbVie from a “buy (b-)” rating to a “buy (b)” rating in a research report on Thursday, October 8th. Finally, Guggenheim upped their price objective on AbbVie from $288.00 to $322.00 and gave the stock a “buy” rating in a research report on Monday, November 2nd. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $297.85.

Read Our Latest Research Report on ABBV

Insider Activity

In other news, EVP Jeffrey Stewart sold 40,619 shares of the stock in a transaction that occurred on Monday, November 9th. The stock was sold at an average price of $293.60, for a total value of $11,925,738.40. Following the completion of the sale, the executive vice president owned 83,171 shares of the company’s stock, valued at approximately $24,419,005.60. This represents a 32.81% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.06% of the stock is currently owned by corporate insiders.

AbbVie Stock Performance

NYSE:ABBV opened at $294.18 on Tuesday. The stock’s 50-day simple moving average is $276.27 and its 200 day simple moving average is $241.28. The company has a market cap of $520.00 billion, a P/E ratio of 50.63, a P/E/G ratio of 1.34 and a beta of 0.20. AbbVie Inc. has a 52-week low of $190.75 and a 52-week high of $302.93.

AbbVie (NYSE:ABBV – Get Free Report) last released its earnings results on Friday, October 30th. The company reported $3.82 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.73 by $0.09. AbbVie had a negative return on equity of 450.55% and a net margin of 15.67%. The business had revenue of $17.40 billion for the quarter, compared to analyst estimates of $17.32 billion. During the same quarter in the prior year, the company posted $1.86 earnings per share. AbbVie’s revenue was up 10.3% on a year-over-year basis. As a group, equities analysts predict that AbbVie Inc. will post 13.98 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 16th. Stockholders of record on Friday, January 15th will be paid a dividend of $1.82 per share. The ex-dividend date is Friday, January 15th. This represents a $7.28 dividend on an annualized basis and a dividend yield of 2.5%. This is an increase from AbbVie’s previous quarterly dividend of $1.73. AbbVie’s dividend payout ratio (DPR) is currently 125.30%.

AbbVie Profile

(Free Report)

AbbVie is a biopharmaceutical company that discovers, develops and markets medicines for a range of serious health conditions. Its research and product portfolio spans immunology, oncology, neuroscience and other therapeutic areas. Key products include the immunology medicines Skyrizi and Rinvoq, cancer treatments such as Imbruvica and Venclexta, and neuroscience therapies including Botox and Vraylar. Through its Allergan acquisition, AbbVie also offers aesthetics products such as Botox Cosmetic and Juvéderm.

Featured Articles

Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.